AUTHOR=Huang Limi , Song Zhiwei , Lu Chaosheng , Wang Shenwen , Guo Changsheng , Lai Xin-He , Zhao Zhenfeng TITLE=A narrative review focusing on randomized clinical trials of vitamin D supplementation for COVID-19 disease JOURNAL=Frontiers in Nutrition VOLUME=11 YEAR=2025 URL=https://www.frontiersin.org/journals/nutrition/articles/10.3389/fnut.2024.1461485 DOI=10.3389/fnut.2024.1461485 ISSN=2296-861X ABSTRACT=

Current evidence is inconsistent on whether vitamin D supplementation can prevent COVID-19 infection or improve its clinical outcomes. To better understand and look into the issue, we went through the background knowledge of COVID-19 and vitamin D, searched in Pubmed [by using key words in the title containing “randomized clinical trial”, “COVID-19”, and “vitamin D (25-hydroxyvitamin D, or cholecalciferol, or calcidiol, or calcifediol) supplementation”] for publications of studies on vitamin D/supplementation in COVID-19 patients, especially those about the randomized clinical trials (RCTs). After reviewing these papers, we did a short background review of vitamin D and the pathophysiology of COVID-19, summarized the key features of the 25 RCTs in text and tabulated in a table of some of the features, commented, compared and discussed the differences between RCTs (for example, change the serum 25-hydroxyvitamin D concentration from nmol/L to ng/mL, making the comparison easier). The take-home question of the review is that serum 25-hydroxyvitamin D concentration is an important indicator of the supplementation effect of vitamin D correction but may not be reliable in predicting the supplementation effect on the clinical outcomes of COVID-19.